Allogeneic cultured keratinocytes and fibroblasts in bovine collagen
| Clinical data | |
|---|---|
| Trade names | Gintuit |
| License data | |
| Routes of administration | Topical |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| DrugBank | |
Allogeneic cultured keratinocytes and fibroblasts in bovine collagen, sold under the brand name Gintuit, is a cellular therapy used for the treatment of mucogingival (the oral mucosa and gingival (gum) tissues of the mouth) conditions.[1][2]
Common adverse reactions observed during clinical trials include sinusitis (sinus inflammation), nasopharyngitis (inflammation of the upper throat, upper respiratory tract infection, aphthous stomatitis (canker sores), and local surgery site reactions such as pain and redness.[2]
Allogeneic cultured keratinocytes and fibroblasts in bovine collagen is a cellular sheet that consists of two layers, an upper layer composed of living human keratinocytes (the primary cell type in the skin's outer layer) and a lower layer constructed of bovine-derived collagen, human extracellular matrix proteins (molecules that support and give structure to cells), and living human dermal fibroblasts (skin cells that generate connective tissues).[2] It is the first cell-based product made from allogeneic (cells derived from a donor source that is unrelated to the intended recipient) human cells and bovine collagen approved by the US Food and Drug Administration (FDA).[2] It was approved for medical use in the United States in March 2012.[1][3][4][5][6]
Medical uses[edit]
Allogeneic cultured keratinocytes and fibroblasts in bovine collagen is indicated for topical (non-submerged) application to a surgically created vascular wound bed in the treatment of mucogingival conditions in adults.[2]
History[edit]
The efficacy of allogeneic cultured keratinocytes and fibroblasts in bovine collagen (Gintuit) was evaluated in two clinical studies in adults with insufficient gingival tissue.[2] In each of the two studies, Gintuit was associated with an increase of at least 2 mm of gingival tissue in at least 50% of the study subjects. The overall clinical trial safety data for Gintuit included 121 subjects from both studies.[2]
References[edit]
- ^ a b c "Gintuit- allogeneic cultured keratinocytes and fibroblasts in bovine collagen cellular sheet". DailyMed. 20 March 2012. Archived from the original on 29 January 2023. Retrieved 23 April 2023.
- ^ a b c d e f g "Gintuit - Questions and Answers". U.S. Food and Drug Administration (FDA). 3 May 2022. Archived from the original on 26 January 2023. Retrieved 23 April 2023.
This article incorporates text from this source, which is in the public domain.
- ^ "Gintuit". U.S. Food and Drug Administration (FDA). 13 May 2022. Archived from the original on 15 March 2023. Retrieved 23 April 2023.
- ^ "2012 Biological License Application Approvals". Center for Biologics Evaluation and Research. 16 February 2012. Archived from the original on 12 January 2017. Retrieved 23 April 2023.
- ^ "Organogenesis Inc. Announces FDA Approval of Gintuit for Oral Soft Tissue Regeneration" (Press release). Organogenesis Inc. 12 March 2012. Archived from the original on 9 August 2022. Retrieved 23 April 2023 – via PR Newswire.
- ^ Schmidt C (June 2012). "Gintuit cell therapy approval signals shift at US regulator". Nature Biotechnology. 30 (6): 479. doi:10.1038/nbt0612-479. PMID 22678374.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |